WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...